{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T05:56:40Z","timestamp":1784872600525,"version":"3.55.0"},"reference-count":131,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1382"],"award-info":[{"award-number":["SFB1382"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["Ta434\/8\\u20131"],"award-info":[{"award-number":["Ta434\/8\\u20131"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["535081457"],"award-info":[{"award-number":["535081457"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRC\/TR 412"],"award-info":[{"award-number":["CRC\/TR 412"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["403224013"],"award-info":[{"award-number":["403224013"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017027","name":"Julius Clinical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020098","name":"Innovative Health Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004907","name":"IHI","doi-asserted-by":"publisher","award":["101132946"],"award-info":[{"award-number":["101132946"]}],"id":[{"id":"10.13039\/501100004907","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cld.2025.12.003","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T21:43:50Z","timestamp":1772228630000},"page":"301-322","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metabolic Liver Disease Beyond the Liver"],"prefix":"10.1016","volume":"30","author":[{"given":"Amalia","family":"Gastaldelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan G.","family":"Holleboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.cld.2025.12.003_bib1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2025.12.003_bib2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.cld.2025.12.003_bib3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2025.12.003_bib4","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits","volume":"77","author":"Peiseler","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.12.003_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1433857","article-title":"Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases","volume":"12","author":"Sandireddy","year":"2024","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.cld.2025.12.003_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101506","article-title":"Steatotic liver disease, MASLD and risk of chronic kidney disease","volume":"50","author":"Bilson","year":"2024","journal-title":"Diabetes Metab"},{"issue":"11","key":"10.1016\/j.cld.2025.12.003_bib7","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1161\/CIRCRESAHA.125.325492","article-title":"Decoding the liver-heart axis in cardiometabolic diseases","volume":"136","author":"Capone","year":"2025","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.cld.2025.12.003_bib8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.gastro.2007.04.068","article-title":"Relationship between hepatic\/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects","volume":"133","author":"Gastaldelli","year":"2007","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.cld.2025.12.003_bib9","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1111\/liv.14556","article-title":"Mechanisms for increased risk of diabetes in chronic liver diseases","volume":"40","author":"Svegliati-Baroni","year":"2020","journal-title":"Liver Int"},{"issue":"11","key":"10.1016\/j.cld.2025.12.003_bib10","article-title":"Hepatic glucose production rises with the histological severity of metabolic dysfunction-associated steatohepatitis","volume":"5","author":"Sabatini","year":"2024","journal-title":"Cell Rep Med"},{"issue":"5","key":"10.1016\/j.cld.2025.12.003_bib11","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1002\/hep.22845","article-title":"Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population","volume":"49","author":"Gastaldelli","year":"2009","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2025.12.003_bib12","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cld.2025.12.003_bib13","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/hep.25539","article-title":"Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in Obese patients with nonalcoholic fatty liver disease","volume":"55","author":"Lomonaco","year":"2012","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2025.12.003_bib14","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jhep.2019.06.031","article-title":"Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease","volume":"71","author":"Rosso","year":"2019","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.12.003_bib15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/j.gastro.2007.11.038","article-title":"Alterations in adipose tissue and hepatic lipid kinetics in Obese men and women with nonalcoholic fatty liver disease","volume":"134","author":"Fabbrini","year":"2008","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.cld.2025.12.003_bib16","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.2337\/diabetes.51.10.3020","article-title":"Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance","volume":"51","author":"Iozzo","year":"2002","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.cld.2025.12.003_bib17","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.2337\/dc23-0871","article-title":"Cardiac insulin resistance in subjects with metabolic syndrome traits and early subclinical atherosclerosis","volume":"46","author":"Devesa","year":"2023","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.cld.2025.12.003_bib18","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.143619","article-title":"Proximal tubular epithelial insulin receptor mediates high-fat diet-induced kidney injury","volume":"6","author":"Lee","year":"2021","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.cld.2025.12.003_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54089-1","article-title":"Profiling of insulin-resistant kidney models and human biopsies reveals common and cell-type-specific mechanisms underpinning diabetic kidney disease","volume":"15","author":"Lay","year":"2024","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.cld.2025.12.003_bib20","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1194\/jlr.M800147-JLR200","article-title":"Ceramide is a cardiotoxin in lipotoxic cardiomyopathy","volume":"49","author":"Park","year":"2008","journal-title":"J Lipid Res"},{"issue":"1","key":"10.1016\/j.cld.2025.12.003_bib21","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/s41467-025-56891-x","article-title":"CerS6 links ceramide metabolism to innate immune responses in diabetic kidney disease","volume":"16","author":"Zhu","year":"2025","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.cld.2025.12.003_bib22","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.2337\/diabetes.51.7.2005","article-title":"Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha","volume":"51","author":"Itani","year":"2002","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.cld.2025.12.003_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cells8030277","article-title":"A new targeted lipidomics approach reveals lipid droplets in liver, muscle and heart as a repository for diacylglycerol and ceramide species in non-alcoholic fatty liver","volume":"8","author":"Preuss","year":"2019","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.cld.2025.12.003_bib24","article-title":"Lipid metabolism in MASLD and MASH: from mechanism to the clinic","volume":"6","author":"Carli","year":"2024","journal-title":"JHEP Rep"},{"issue":"6451","key":"10.1016\/j.cld.2025.12.003_bib25","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1126\/science.aav3722","article-title":"Targeting a ceramide double bond improves insulin resistance and hepatic steatosis","volume":"365","author":"Chaurasia","year":"2019","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.cld.2025.12.003_bib26","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/ATVBAHA.114.305200","article-title":"Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the framingham heart study","volume":"35","author":"Long","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.cld.2025.12.003_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1034\/j.1600-0676.2000.020001003.x","article-title":"Morphological mechanisms for regulating blood flow through hepatic sinusoids","volume":"20","author":"McCuskey","year":"2000","journal-title":"Liver"},{"issue":"6","key":"10.1016\/j.cld.2025.12.003_bib28","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jhep.2019.02.012","article-title":"Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease","volume":"70","author":"Hammoutene","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.cld.2025.12.003_bib29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev-physiol-022516-034227","article-title":"Mechanisms of renal fibrosis","volume":"80","author":"Humphreys","year":"2018","journal-title":"Annu Rev Physiol"},{"issue":"4","key":"10.1016\/j.cld.2025.12.003_bib30","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2008.06.012","article-title":"Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review","volume":"49","author":"Sookoian","year":"2008","journal-title":"J Hepatol"},{"issue":"17","key":"10.1016\/j.cld.2025.12.003_bib31","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cld.2025.12.003_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-025-00599-1","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults","volume":"11","author":"Huang","year":"2025","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"10.1016\/j.cld.2025.12.003_bib33","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","article-title":"Hepatic inflammatory responses in liver fibrosis","volume":"20","author":"Hammerich","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.cld.2025.12.003_bib34","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/s41423-025-01307-5","article-title":"Immunopathogenic mechanisms and immunoregulatory therapies in MASLD","volume":"22","author":"He","year":"2025","journal-title":"Cell Mol Immunol"},{"issue":"7","key":"10.1016\/j.cld.2025.12.003_bib35","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41575-025-01068-6","article-title":"Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease","volume":"22","author":"Schwabe","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2025.12.003_bib36","article-title":"Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease","volume":"7","author":"Schwabe","year":"2025","journal-title":"JHEP Rep"},{"issue":"11","key":"10.1016\/j.cld.2025.12.003_bib37","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/j.cmet.2022.09.017","article-title":"Gut-liver axis: pathophysiological concepts and clinical implications","volume":"34","author":"Tilg","year":"2022","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.cld.2025.12.003_bib38","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.cld.2025.12.003_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0299507","article-title":"Increased risk of chronic kidney disease and mortality in a cohort of people diagnosed with metabolic dysfunction associated steatotic liver disease with hepatic fibrosis","volume":"19","author":"Gurun","year":"2024","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.cld.2025.12.003_bib40","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1253\/circrep.CR-25-0019","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) is an independent risk factor for the development of ischemic heart disease \u2015 A 10-Year cohort study","volume":"7","author":"Ogawa","year":"2025","journal-title":"Circ Rep"},{"issue":"2","key":"10.1016\/j.cld.2025.12.003_bib41","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/HEP.0000000000000735","article-title":"Metabolic dysfunction-associated steatotic liver disease and the heart","volume":"82","author":"Driessen","year":"2025","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2025.12.003_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2021.12.012","article-title":"Why does obesity cause diabetes?","volume":"34","author":"Klein","year":"2022","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.cld.2025.12.003_bib43","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Investig"},{"key":"10.1016\/j.cld.2025.12.003_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2020.100130","article-title":"Inflammation and cardiovascular disease: from mechanisms to therapeutics","volume":"4","author":"Alfaddagh","year":"2020","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.cld.2025.12.003_bib45","article-title":"Distinct circulating cytokine levels in patients with angiography-proven coronary artery disease compared to disease-free controls","volume":"22","author":"Maaniitty","year":"2024","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"issue":"12","key":"10.1016\/j.cld.2025.12.003_bib46","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.cld.2025.12.003_bib47","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cld.2025.12.003_bib48","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2180373","article-title":"Inflammation-related mechanisms in chronic kidney disease prediction, progression, and outcome","volume":"2018","author":"Mihai","year":"2018","journal-title":"J Immunol Res"},{"issue":"5","key":"10.1016\/j.cld.2025.12.003_bib49","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/MEG.0000000000001541","article-title":"Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"32","author":"Wijarnpreecha","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2025.12.003_bib50","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13947","article-title":"Small intestinal bacterial overgrowth and non-alcoholic fatty liver disease diagnosed by transient elastography and liver biopsy","volume":"75","author":"Mikolasevic","year":"2021","journal-title":"Int J Clin Pract"},{"issue":"12","key":"10.1016\/j.cld.2025.12.003_bib51","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1111\/liv.14696","article-title":"Intestinal permeability in human nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"40","author":"De Munck","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2025.12.003_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102649","article-title":"The gut microbiome in coronary artery disease and heart failure: current knowledge and future directions","volume":"52","author":"Troseid","year":"2020","journal-title":"EBioMedicine"},{"issue":"7","key":"10.1016\/j.cld.2025.12.003_bib53","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015292","article-title":"Association of small intestinal bacterial overgrowth with heart failure and its prediction for short-term outcomes","volume":"10","author":"Song","year":"2021","journal-title":"J Am Heart Assoc"},{"issue":"17","key":"10.1016\/j.cld.2025.12.003_bib54","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1109400","article-title":"Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk","volume":"368","author":"Tang","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cld.2025.12.003_bib55","doi-asserted-by":"crossref","first-page":"386","DOI":"10.21037\/hbsn-22-421","article-title":"An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease","volume":"12","author":"Sun","year":"2023","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"2","key":"10.1016\/j.cld.2025.12.003_bib56","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jhep.2025.08.017","article-title":"Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD","volume":"84","author":"Zhou","year":"2025","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2025.12.003_bib57","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cmet.2007.10.011","article-title":"Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin","volume":"6","author":"Takahashi","year":"2007","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.cld.2025.12.003_bib58","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/oby.2007.114","article-title":"ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats","volume":"16","author":"Toblli","year":"2008","journal-title":"Obesity (Silver Spring)"},{"issue":"18","key":"10.1016\/j.cld.2025.12.003_bib59","doi-asserted-by":"crossref","first-page":"6531","DOI":"10.1073\/pnas.0802690105","article-title":"Mice lacking angiotensin-converting enzyme have increased energy expenditure, with reduced fat mass and improved glucose clearance","volume":"105","author":"Jayasooriya","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.cld.2025.12.003_bib60","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.2353\/ajpath.2009.080697","article-title":"Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats","volume":"174","author":"Wei","year":"2009","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.cld.2025.12.003_bib61","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jhep.2008.03.018","article-title":"Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats","volume":"49","author":"Wei","year":"2008","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2025.12.003_bib62","article-title":"Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD","volume":"4","author":"van der Graaff","year":"2022","journal-title":"JHEP Rep"},{"issue":"5","key":"10.1016\/j.cld.2025.12.003_bib63","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacc.2020.11.059","article-title":"Local pressure drives low-density lipoprotein accumulation and coronary atherosclerosis in hypertensive minipigs","volume":"77","author":"Al-Mashhadi","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.cld.2025.12.003_bib64","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1172\/JCI18212","article-title":"NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis","volume":"112","author":"Bataller","year":"2003","journal-title":"J Clin Investig"},{"issue":"99","key":"10.1016\/j.cld.2025.12.003_bib65","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1111\/j.1523-1755.2005.09911.x","article-title":"The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease","author":"Remuzzi","year":"2005","journal-title":"Kidney Int Suppl"},{"issue":"6","key":"10.1016\/j.cld.2025.12.003_bib66","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000313363","article-title":"Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease","volume":"31","author":"Siragy","year":"2010","journal-title":"Am J Nephrol"},{"issue":"3","key":"10.1016\/j.cld.2025.12.003_bib67","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2025.12.003_bib68","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/gutjnl-2023-331003","article-title":"Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease","volume":"73","author":"Lee","year":"2024","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.cld.2025.12.003_bib69","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.14309\/ajg.0000000000003274","article-title":"Cardiovascular risk from metabolic dysfunction-associated steatotic liver disease, cardiometabolic risk factor count, and their longitudinal changes: a nationwide cohort study","volume":"120","author":"Lee","year":"2025","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2025.12.003_bib70","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.cgh.2023.09.018","article-title":"Longitudinal outcomes associated with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of 129 studies","volume":"22","author":"Chan","year":"2024","journal-title":"Clin Gastroenterol H"},{"issue":"9","key":"10.1016\/j.cld.2025.12.003_bib71","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/hepr.14226","article-title":"Chronic kidney disease risk associated with metabolic dysfunction-associated steatotic liver disease: a nationwide cohort study in Korea","volume":"55","author":"Kim","year":"2025","journal-title":"Hepatol Res"},{"issue":"19","key":"10.1016\/j.cld.2025.12.003_bib72","doi-asserted-by":"crossref","first-page":"14651","DOI":"10.3390\/ijms241914651","article-title":"Fatty Liver Index (FLI) identifies not only individuals with liver steatosis but also at high cardiometabolic risk","volume":"24","author":"Carli","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.cld.2025.12.003_bib73","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12933-021-01374-8","article-title":"The association of hepatic steatosis and fibrosis with heart failure and mortality","volume":"20","author":"Park","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.cld.2025.12.003_bib74","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1007\/s10620-021-06954-y","article-title":"Fatty liver index and development of cardiovascular disease: findings from the UK biobank","volume":"66","author":"Zou","year":"2021","journal-title":"Dig Dis Sci"},{"issue":"7","key":"10.1016\/j.cld.2025.12.003_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180951","article-title":"The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort study","volume":"12","author":"Huh","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cld.2025.12.003_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(24)01877-4","article-title":"A narrative review of lifestyle management guidelines for metabolic dysfunction-associated steatotic liver disease","author":"Wajcman","year":"2024","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2025.12.003_bib77","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/j.gastro.2025.02.044","article-title":"Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis","volume":"169","author":"Younossi","year":"2025","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.cld.2025.12.003_bib78","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","article-title":"Lifestyle interventions in nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2025.12.003_bib79","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12933-025-02700-0","article-title":"CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes","volume":"24","author":"Schnell","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cld.2025.12.003_bib80","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.2337\/dc25-S004","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in Diabetes-2025","volume":"48","author":"Elsayed","year":"2025","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.cld.2025.12.003_bib81","first-page":"e34572","article-title":"Lifestyle modifications and nutritional and therapeutic interventions in delaying the progression of chronic kidney disease: a review","volume":"15","author":"Alkhatib","year":"2023","journal-title":"Cureus J Med Science"},{"issue":"6","key":"10.1016\/j.cld.2025.12.003_bib82","doi-asserted-by":"crossref","first-page":"e0711","DOI":"10.1097\/HC9.0000000000000711","article-title":"Skeletal muscle and MASLD: mechanistic and clinical insights","volume":"9","author":"Marjot","year":"2025","journal-title":"Hepatol Commun"},{"issue":"10019","key":"10.1016\/j.cld.2025.12.003_bib83","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"10","key":"10.1016\/j.cld.2025.12.003_bib84","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/db23-0972","article-title":"GLP-1 receptor agonist treatment improves fasting and postprandial lipidomic profiles independently of diabetes and weight loss","volume":"73","author":"Della","year":"2024","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.cld.2025.12.003_bib85","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/dom.12836","article-title":"Effect of exenatide on postprandial glucose fluxes, lipolysis, and beta-cell function in non-diabetic, morbidly obese patients","volume":"19","author":"Camastra","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.cld.2025.12.003_bib86","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.cld.2025.12.003_bib87","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.cld.2025.12.003_bib88","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.cld.2025.12.003_bib89","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cld.2025.12.003_bib90","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.cld.2025.12.003_bib91","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/apt.17925","article-title":"Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes","volume":"59","author":"Elsaid","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.cld.2025.12.003_bib92","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/gutjnl-2024-332687","article-title":"Risk of hepatic events associated with use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists, and thiazolidinediones among patients with metabolic dysfunction-associated steatotic liver disease","volume":"74","author":"Bea","year":"2025","journal-title":"Gut"},{"issue":"11\u201312","key":"10.1016\/j.cld.2025.12.003_bib93","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/apt.18331","article-title":"Semaglutide 2.4 mg in Participants with Metabolic Dysfunction-Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE trial","volume":"60","author":"Newsome","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.cld.2025.12.003_bib94","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1038\/s41591-025-03799-0","article-title":"Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"31","author":"Jara","year":"2025","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.cld.2025.12.003_bib95","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.cld.2025.12.003_bib96","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2025.12.003_bib97","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A phase 2 randomized trial of survodutide in MASH and fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.cld.2025.12.003_bib98","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.jchf.2024.09.004","article-title":"Survodutide for the treatment of obesity: rationale and design of the SYNCHRONIZE cardiovascular outcomes trial","volume":"12","author":"Kosiborod","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"4","key":"10.1016\/j.cld.2025.12.003_bib99","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-Gomez","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2025.12.003_bib100","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J Hepatol"},{"issue":"Supplement_1","key":"10.1016\/j.cld.2025.12.003_bib101","doi-asserted-by":"crossref","DOI":"10.2337\/db25-749-P","article-title":"749-P: integrated analysis supports cardiovascular safety and risk reduction with pemvidutide treatment","volume":"74","author":"Tomah","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.cld.2025.12.003_bib102","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.cld.2025.12.003_bib103","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/j.ekir.2025.03.049","article-title":"The effect of retatrutide on kidney parameters in participants with type 2 diabetes mellitus and\/or obesity","volume":"10","author":"Heerspink","year":"2025","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1016\/j.cld.2025.12.003_bib104","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2337\/dc23-1646","article-title":"Empagliflozin reduces liver fat in individuals with and without diabetes","volume":"47","author":"Abdelgani","year":"2024","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.cld.2025.12.003_bib105","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","author":"Cusi","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.cld.2025.12.003_bib106","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/dom.14670","article-title":"Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes","volume":"24","author":"Kahl","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.cld.2025.12.003_bib107","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1097\/HEP.0000000000000855","article-title":"Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: a randomized, double-blind, placebo-controlled trial","volume":"80","author":"Cheung","year":"2024","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2025.12.003_bib108","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123130","article-title":"SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms","volume":"4","author":"Osataphan","year":"2019","journal-title":"JCI Insight"},{"issue":"22","key":"10.1016\/j.cld.2025.12.003_bib109","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.cld.2025.12.003_bib110","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cld.2025.12.003_bib111","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.cld.2025.12.003_bib112","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with Ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cld.2025.12.003_bib113","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13098-024-01547-x","article-title":"Evaluating the overall renal outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD)","volume":"17","author":"Cao","year":"2025","journal-title":"Diabetol Metab Syndr"},{"issue":"5","key":"10.1016\/j.cld.2025.12.003_bib114","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.cld.2025.12.003_bib115","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"9976","key":"10.1016\/j.cld.2025.12.003_bib116","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Cholesterol Treatment Trialists","year":"2015","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.cld.2025.12.003_bib117","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2023.11.012","article-title":"Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease","volume":"122","author":"Mellemkjaer","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"38","key":"10.1016\/j.cld.2025.12.003_bib118","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.2174\/1381612825666190117114305","article-title":"The role of statins in the management of Nonalcoholic Fatty liver disease","volume":"24","author":"Doumas","year":"2018","journal-title":"Curr Pharm Des"},{"issue":"4","key":"10.1016\/j.cld.2025.12.003_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101816","article-title":"Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis","volume":"46","author":"Fatima","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2025.12.003_bib120","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1053\/j.gastro.2009.01.053","article-title":"Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes","volume":"136","author":"El-Serag","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2025.12.003_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104392","article-title":"Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study","volume":"87","author":"Ayada","year":"2023","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.cld.2025.12.003_bib122","doi-asserted-by":"crossref","first-page":"G724","DOI":"10.1152\/ajpgi.00063.2016","article-title":"Statins improve NASH via inhibition of RhoA and Ras","volume":"311","author":"Schierwagen","year":"2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"25","key":"10.1016\/j.cld.2025.12.003_bib123","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to Statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.cld.2025.12.003_bib124","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.cld.2025.12.003_bib125","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cld.2025.12.003_bib126","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.cld.2025.12.003_bib127","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/ATVBAHA.112.301187","article-title":"Ezetimibe inhibits hepatic Niemann-Pick C1-Like 1 to facilitate macrophage reverse cholesterol transport in mice","volume":"33","author":"Xie","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.cld.2025.12.003_bib128","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.3892\/mmr.2014.2623","article-title":"Ezetimibe prevents the development of non-alcoholic fatty liver disease induced by high-fat diet in C57BL\/6J mice","volume":"10","author":"Wang","year":"2014","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.cld.2025.12.003_bib129","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.595819","article-title":"PCSK9 inhibition: insights from clinical trials and future prospects","volume":"11","author":"Katzmann","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.cld.2025.12.003_bib130","series-title":"Assessing the impact of PCSK9 inhibitors in steatotic liver disease. A prospective observational cohort study (SIMPLE)","author":"George","year":"2024"},{"issue":"4","key":"10.1016\/j.cld.2025.12.003_bib131","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/MOL.0000000000000878","article-title":"Bempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of action","volume":"34","author":"Roglans","year":"2023","journal-title":"Curr Opin Lipidol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125001059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326125001059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:58:25Z","timestamp":1778878705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326125001059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":131,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1089326125001059"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2025.12.003","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic Liver Disease Beyond the Liver","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2025.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}